

**SİKLOFOSFAMİD KAYNAKLI
KARACİĞER HASARI VE VİTAMİN D3**

Abdulsamet EFDAL

© Copyright 2020

Bu kitabın, basım, yayın ve satış hakları Akademisyen Kitabevi A.Ş.'ne aittir. Anılan kuruluşun izni alınmadan kitabın tümü ya da bölümleri mekanik, elektronik, fotokopi, manyetik kağıt ve/veya başka yöntemlerle çoğaltılamaz, basılamaz, dağıtılamaz. Tablo, şekil ve grafikler izin alınmadan, ticari amaçlı kullanılamaz. Bu kitap T.C. Kültür Bakanlığı bandrolü ile satılmaktadır.

* Bu Kitap "Siklofosamid İle Oluşturulmuş Karaciğer Hasarı Üzerine Vitamin D3'ün Etkileri" isimli tezden üretilmiştir.

ISBN

978-625-7795-22-7

Kitap Adı

Siklofosamid Kaynaklı Karaciğer Hasarı ve Vitamin D3

Yazar

Abdulsamet EFDAL

Yayın Koordinatörü

Yasin Dilmen

Sayfa ve Kapak Tasarımı

Akademisyen Dizgi Ünitesi

Yayıncı Sertifika No

47518

Baskı ve Cilt

Vadi Matbaacılık

Bisac Code

MED110000

GENEL DAĞITIM

Akademisyen Kitabevi A.Ş.

Halk Sokak 5 / A

Yenişehir / Ankara

Tel: 0312 431 16 33

siparis@akademisyen.com

www.akademisyen.com

**Canım Eşim Seda, Biricik Kızım Zeynep Nisa ve
Can Oğlum Bekir Talha'ya...**

TEŞEKKÜR

Yüksek lisans eğitimim süresince ilminden faydalandığım, insani ve ahlaki değerleri ile de örnek edindiğim, yanında çalışmaktan onur duyduğum ve ayrıca tez konumun seçimi, yürütülmesi ve değerlendirilmesinde tecrübelerinden yararlandığım değerli danışman hocam Prof. Dr. Neriman ÇOLAKOĞLU'na,

Bilgi ve deneyimlerinden yararlandığım diğer değerli hocalarım; Prof. Dr. İbrahim Enver OZAN, Prof. Dr. Dürrin Özlem DABAK ve Prof. Dr. Leyla CANPOLAT KOYUTÜRK'e; tezimin her aşamasında desteğini gördüğüm, deneyiminden ve bilgisinden faydalandığım Fırat Üniversitesi Histoloji ve Embriyoloji Anabilim Dalı'ndan saygıdeğer hocalarım; Doç. Dr. Tuncay KULOĞLU'na ve Dr. Öğr. Üyesi Nevin KOCAMAN'a, Tezime sağladığı finansmandan ötürü Fırat Üniversitesi Bilimsel Araştırma Projeleri Birimi (FÜBAP) 'ne, manevi desteğini esirgemeyen aileme sonsuz teşekkür ederim.

İÇİNDEKİLER

TEŞEKKÜR	v
KISALTMALAR	xii
GİRİŞ	1
Karaciğer Anatomisi.....	1
Karaciğerin Lobları.....	2
Bağları.....	3
Arterleri.....	3
Venleri.....	4
Lenf Drenajı.....	4
Sinirleri.....	5
Karaciğerin Fizyolojisi.....	5
Karaciğerin Damar ve Lenf Sistemleri.....	6
Karaciğer Kütlesinin Düzenlenmesi - Yenilenmesi. 7	
Karaciğerin Makrofaj Sistemi - Karaciğerin	
Kan Temizleme İşlevi.....	9

Karaciğerin Metabolik İşlevleri.....	9
Karbonhidrat Metabolizması.....	9
Yağ Metabolizması.....	10
Protein Metabolizması.....	10
Karaciğerin Diğer Metabolik İşlevleri	10
Vitaminlerin Depo Edilmesi	10
Karaciğerin Demiri Ferritin Şeklinde Depolaması	11
Kan Pıhtılaşması ile Karaciğerin İlişkisi.....	11
İlaçların, Hormonların ve Diğer Maddelerin Karaciğer Tarafından Uzaklaştırılması	11
Karaciğerin Embriyolojisi	12
Karaciğer ve Peritonla İlişkisi.....	13
Fetal Karaciğerin İşlevi	13
Karaciğerin Histolojisi.....	14
Stroma.....	14
Karaciğer Lobülü.....	14
Karaciğer Asinüsünün Yapısı ve İşlevi	16
Karaciğer Hücresi (Hepatosit).....	18
Hepatositlerin İnce Yapısı ve İşlevi	20
Karaciğer Sinüzoidlerinin İnce Yapısı	21
Disse Aralığının İnce Yapısı.....	23
Karaciğer Parankiminin Histolojik Yerleşimi.....	24
Glisson Kapsülünün Histolojisi	25
Portal Triadlardaki Kan ve Safra Akımı.....	25

Portal Yolun (Trakt) ve Santral Venin Histolojisi...	26
Safra Kanaliküllerinin İnce Yapısı ve İşlevi	27
Siklofosfamid.....	29
Yapısı ve Özellikleri	29
Siklofosfamid Metabolizması.....	30
Oksidatif Stres.....	32
Antioksidan Mekanizmalar	33
Vitamin D	34
1,25(OH)2D'nin Etkisi.....	37
Deney Hayvanları	41
GEREÇ VE YÖNTEM.....	41
Deney Gruplarının Oluşturulması ve Deneysel Uygulamalar.....	42
Histolojik Çalışma	43
TUNEL Metodu	44
BULGULAR.....	47
TARTIŞMA.....	59
KAYNAKLAR.....	67

KAYNAKLAR

1. Arıncı K, Elhan A. Anatomi 1. Cilt: Kemikler, eklemler, kaslar, iç organlar. 4. Baskı, Ankara: Güneş, 2006.
2. Drake RL, Vogl W, Mitchell AWM. Yıldırım M (Çeviren). Gray's Tıp Fakültesi Öğrencileri İçin Anatomi. 1. Baskı, Ankara: Güneş, 2007.
3. <http://www.meddean.luc.edu/lumen/MedEd/Histo/frames/hfram19.html>. 10.03.2013.
4. Barrett KE, Barman SM, Boitano S, Brooks HL. Ganong'un Tıbbi Fizyolojisi. Gökbel H (Çeviren). 23. Baskı, İstanbul: Nobel, 2011.
5. Guyton AC, Hall JE. Tıbbi Fizyoloji. Çavuşoğlu H, Yeğen BÇ (Çeviren). 11. Baskı, İstanbul: Nobel, 2007.
6. Preston RR, Wilson TE. Lippincott Görsel Anlatımlı Çalışma Kitapları: Fizyoloji. Alkaç Üİ (Çeviren). 1. Baskı, İstanbul: Nobel, 2013.
7. Moore KL, Persaud TVN. Embriyoloji ve Doğum Defektlerinin Temelleri. Müftüoğlu S, Atilla P, Kaymaz F (Çeviren). 7. Baskı, Ankara: Güneş, 2009.
8. Sadler TW. Langman's Medikal Embriyoloji. Başaklar AC (Çeviren). 6. Baskı, Ankara: Palme, 1993.
9. Eşrefoğlu M. Özel Histoloji. 1. Baskı, Malatya: Medipres, 2009.
10. Junqueira LC, Carneiro J. Temel Histoloji. Solakoğlu S, AYTEKİN Y (Çeviren). 11. Baskı, İstanbul: Nobel, 2009.

11. Kierszenbaum AL. Histoloji ve Hücre Biyolojisi, Patolojiye Giriş. Demir R (Çeviren). 5. Baskı, Ankara: Palme, 2006.
12. Cowley AW Jr, Mori T, Mattson D, Zou AP. Role of renal NO production in the regulation of medullary blood flow. *Am J Physiol Regul Integr Comp Physiol* 2003; 284: 1355-1369.
13. Ovalle WK, Nahirney PC. Netter's Essential Histology. Müftüoğlu S, Kaymaz F, Atilla P (Çeviren). 1. Baskı, Ankara: Güneş, 2009.
14. www.octc.kctcs.edu/gcaplan/anat2/notes8%20digestive 20.03.2013.
15. Eroschenko VP. Histoloji Atlası. Demir R (Çeviren). 10. Baskı, Ankara: Palme, 2008.
16. Ge ZD, Zhang DX, Chen YF, et al. Cyclic ADP-ribose contributes to contraction and Ca²⁺ release by M1 muscarinic receptor activation in coronary arterial smooth muscle. *J Vasc Res* 2003; 40: 28-36.
17. Nafees S, Ahmad ST, Arjumand W, et al. Modulatory effects of genitric acid against genotoxicity and hepatotoxicity induced by cyclophosphamide in Swiss albino mice. *J Pharm and Pharmacol* 2011; 64: 259-267.
18. <http://www.sigmaaldrich.com/catalog/product/sigma/c7397?lang=en®ion=TR> 12.04.2013.
19. Tripathi DN, Jena GB. Astaxanthin inhibits cytotoxic and genotoxic effects of cyclophosphamide in mice germ cells. *Toxicology* 2008; 248: 96-103.
20. Fiorucci E, Lucantoni G, Paone G, et al. Cyclophosphamide and prednisone in the treatment of mild-moderate idiopathic pulmonary fibrosis: comparison of three currently available therapeutic regimens. *Eur Rev Med Pharmacol Sci* 2008; 12: 105-111.
21. Starzl TE, Putnam CW, Halgrimson CG, et al. Cyclophosphamide and whole organ transplantation in human beings. *Surg Gynecol Obstet* 1971; 133: 981-991.
22. Uber WE, Self SE, Van Bakel AB, Pereira NL. Acute antibody-mediated rejection following heart transplantation. *Am J Transplant* 2007; 7: 2064-2074.
23. Fraiser LH, Kanekal S, Kehrer JP. Cyclophosphamide toxicity. Characterising and avoiding the problem. *Drugs* 1991; 42: 781-795.
24. Borgmann A, Zinn C, Hartmann R, et al. Secondary malignant neoplasms after intensive treatment of relapsed acute lymphoblastic leukaemia in childhood. *Eur J Cancer* 2008; 44: 257-268.
25. Tripathi DN, Jena GB. Intervention of astaxanthin against cyclophosphamide-induced oxidative stress and DNA damage: A study in mice. *Chemico-Biological Interactions* 2009; 180: 398-406.

26. Rekhadevi PV, Sailaja N, Chandrasekhar M, et al. Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. *Mutagenesis* 2007; 22: 395-401.
27. Ahmad S, Mika D, Guruvayoorapan C. Chemoprotective and immunomodulatory effect of *Acacia nilotica* during cyclophosphamide induced toxicity. *J Exp Ther Oncol* 2012; 10: 83- 90.
31. Nepomnyashchikh LM, Molodykh OP, Lushnikova EL, and Sorokina YA. Morphogenesis and histostereological analysis of hepatopathy induced by cyclophosphamide. *Bull Eksp Biol Med* 2010; 150: 104-120.
32. Bayramoğlu G. Sıçanlarda Siklofosfamid İle Oluşturulmuş Oksidatif Strese Karşı Silimarinin Olası Koruyucu Etkileri. Doktora Tezi, Eskişehir: Osmangazi Üniversitesi, Fen Bilimleri Enstitüsü, 2007.
33. Tripathi DN, Jena GB. Ebselen attenuates cyclophosphamide-induced oxidative stress and DNA damage in mice. *Free Rad Res* 2008; 967-977.
34. Pal A, Hu X, Zimniak P, Singh SV. Catalytic efficiencies of allelic variants of human glutathione-S-transferase Pi in the glutathione conjugation of α,β unsaturated aldehydes. *Cancer Lett* 2000; 154: 39-43.
35. Uchida K, Kanematsu M, Morimitsu Y, et al. Acrolein is a product of lipid peroxidation reaction. *J Biol Chem* 1998; 273: 16058-16066.
36. Kern JC, Kehrer JP. Acrolein-induced cell death: a caspase-influenced decision between apoptosis and oncosis/necrosis. *Chem Biol Interact* 2002; 139: 79-95.
37. Hales BE. Comparison of the mutagenicity and teratogenicity of cyclophosphamide and its active metabolites, 4-hydroxycyclophosphamide, phosphoramidate mustard and acrolein. *Cancer Res* 1982; 42: 3016-3021.
38. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. *Cell Biol Toxicol* 2007; 23: 303-3012.
39. Bendich A. Antioxidant nutrients and immune functions – introduction. *Adv Exp Med Biol* 1990; 262: 1-12.
40. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. *Free Radic Biol Med* 2000; 29: 323-333.
41. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. *Proc Natl Acad Sci USA* 1988; 85: 6465-6467.

42. Wei XJ, Hu TJ, Chen JR, Wei YY. Inhibitory effect of carboxymethylpachymaran on cyclophosphamide-induced oxidative stress in mice. *Int J Biol Macromol* 2011; 49: 801- 805.
43. Motawi TM, Sadik NA, Refaat A. Cytoprotective effects of DL-alpha-lipoic acid or squalene on cyclophosphamideinduced oxidative injury: an experimental study on rat myocardium, testicles and urinary bladder. *Food Chem Toxicol* 2010; 48: 2326-2336.
44. Jnaneshwari S, Hemshekhar M, Santhosh MS, Sunitha K, et al. Crocin, a dietary colorant mitigates cyclophosphamide-induced organ toxicity by modulating antioxidant status and inflammatory cytokines. *J Pharm and Pharmacol* 2012; 604-614.
45. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. *Cancer Treat Rev* 1997; 23: 209-240.
46. Stankiewicz A, Skrzydlewska E. Protection against cyclophosphamide-induced renal oxidative stress by amifostine: the role of antioxidative mechanisms. *Toxicol Mech Methods* 2003; 13: 301-308.
47. Serafini M, Del Rio D. Understanding the association between dietary antioxidants, redox status and disease: is the total antioxidant capacity the right tool? *Redox Report* 2004; 9: 145-152.
48. Altan N, Dinçel AS, Koca C. Diabetes mellitus ve oxidative stress. *Turk J Biochem* 2006; 31: 51-56.
49. Halliwell B. Antioxidant characterization. Methodology and mechanism. *Biochem Pharmacol* 1995; 49: 1341-1348.
50. Beckman KB, Ames BN. The free radical theory of aging matures. *Physiol Rev* 1998; 78: 547-581.
51. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. *Clin Chem* 1995; 41: 1819-1828.
52. Bouillon R, Moody T, Sporn M, Barrett JC, Norman AW. NIH deltanoids meeting on vitamin D and cancer conclusion and strategic options. *J Steroid Biochem Mol Biol* 2005; 97: 3-5.
53. Van Etten E, Mathieu C. Immunoregulation by 1, 25-dihydroxyvitamin D3: basic concepts. *J Steroid Biochem Mol Biol* 2005; 97: 93-101.
54. Mizobuchi M, Ogata H, Koiwa F, Kinugasa E, Akizawa T. Vitamin D and vascular calcification in chronic kidney disease. *Bone* 2009; 45: 26-29.
55. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. *Arch Intern Med* 2008; 168: 1340-1349.

56. Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. *Prev Med* 2010; 51: 228-233.
57. Kono K, Fujii H, Nakai K. Anti-oxidative effect of vitamin D analog on incipient vascular lesion in non-obese type 2 diabetic rats. *Am J Nephrol* 2013; 37: 167-174.
58. Zempleni J, Rucker RB. *Handbook of vitamins*. 4th ed. CRC Press 2008.
59. Rucker RB. *Handbook of vitamins*. Marcel Dekker, Inc 2001.
60. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than Vitamin D3 in humans. *J Clin Endocrinol Metab* 2004; 89: 5387-5391.
61. Lips P. Vitamin D physiology. *Prog Biophys Mol Biol* 2006; 92: 4-8.
62. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. *Diabetes Obes Metab* 2008; 10: 185-197.
63. Muller K, Diamant M, Bendtzen K. Inhibition of production and function of interleukin-6 by 1,25-dihydroxyvitamin D3. *Immunology Letters* 1991; 28: 115-120.
64. Bouillon R, Garmyn M, Verstuyf A, Segaert S, Casteels K, Mathieu C. Paracrine role for calcitriol in the immune system and skin creates new therapeutic possibilities for vitamin D analogs. *Eur J Endocrinol* 1995; 133: 7-16.
65. DeLuca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. *FASEB J* 2001; 15: 2579-2585.
66. Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM. Intake of vitamin D and risk of type 1 diabetes: A birth-cohort study. *Lancet* 2001; 358: 1500-1503.
67. Merlino L, Curtis J, Mikuls TR, et al. Vitamin D intake is inversely associated with rheumatoid arthritis. Results from the Iowa Women's Health Study. *Arthritis and Rheum* 2004; 50: 72-77.
68. Zella JB, McCary LC, DeLuca HF. Oral administration of 1,25-dihydroxyvitamin D3 completely protects NOD mice from insulin-dependent diabetes mellitus. *Arch Biochem Biophys* 2003; 417: 77-80.
69. Mathieu C, Van Etten E, Decallonne B, et al. Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. *J Steroid Biochem Mol Biol* 2004; 89-90: 449-452.
70. Aksoy H, Akçay F, Kurtul N, et al. Serum 1,25-dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. *Clin Biochem* 2000; 33: 47-51.

71. Kadowski S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. *J Clin Invest* 1984; 73: 759-766.
72. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. *Cancer J* 2010; 16: 1-9.
73. Fleet JC, Desmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. *Biochem J* 2012; 221: 61-76.
74. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. *Endocrinol Metab Clin N Am* 2010; 39: 401-418.
75. Ting HJ, Yasmin-Karim S, Hsu JW, et al. A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. *Cancer Res* 2012; 72: 958-968.
76. Wong G, Gupta R, Dixon KM, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. *J Steroid Biochem Mol Biol* 2004; 89-90: 567-570.
77. De Haes P, Garmyn M, Verstuyf A, et al. 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. *J Photochem Photobiol B* 2005; 78: 141-148.
78. Chatterjee M. Vitamin D and genomic stability. *Mutat Res* 2001; 475: 69-87.
79. Wu-Wong JR, Nakane M, Ma J, et al. Effects of Vitamin D analogs on gene expression profiling in human coronary artery smooth muscle cells. *Atherosclerosis* 2006; 186: 20-28.
80. Haussler MR, Haussler CA, Whitfield GK, et al. The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the "Fountain of Youth" to mediate healthful aging. *J Steroid Biochem Mol Biol* 2010; 121: 88-97.
81. Marnett LJ, Riggins JN, West JD. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. *J Clin Invest* 2003; 111: 583-593.
82. Jameson JL. Harrison Endokrinoloji. Bereket A, Akçay T (Çeviren). 2. Baskı, İstanbul: Nobel, 2013.
83. Kallay E, Pietschmann P, Toyokuni S, et al. Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. *Carcinogenesis* 2001; 22: 1429-1435.

84. Fedirko V, Bostick RM, Long Q, et al. Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: a randomized clinical trial. *Cancer Epidemiol. Biomarkers Prev* 2010; 19: 280-291.
85. Peehl DM, Shinghal R, Nonn L, et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. *J Steroid Biochem Mol Biol* 2004; 92: 131-141.
86. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, et al. Genetic signatures of differentiation induced by 1 α ,25-dihydroxyvitamin D3 in human colon cancer cells. *Cancer Res* 2003; 63: 7799-7806.
87. Swami S, Raghavachari N, Muller UR, Bao YP, Feldman D. Vitamin D growth inhibition of breast cancer cells: gene expression patterns assessed by cDNA microarray. *Breast Cancer Res Treat* 2003; 80: 49-62.
88. Lambert JR, Kelly JA, Shim M, et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. *J Cell Physiol* 2006; 208: 566-574.
89. Hamden K, Carreau S, Jamoussi K, et al. 1 α ,25 dihydroxyvitamin D3: therapeutic and preventive effects against oxidative stress, hepatic, pancreatic and renal injury in alloxan- induced diabetes in rats. *J Nutr Sci Vitaminol* 2009; 55: 215-222.
90. Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague–Dawley rats. *Int J Vitam Nutr Res* 1996; 66: 39-45.
91. Dong J, Wong SL, Lau CW, et al. Calcitriol protects renovascular function in hypertension by down-regulating angiotensin II type 1 receptors and reducing oxidative stress. *Eur Heart J* 2012; 33: 2980-2990.
92. Perini P, Calabrese M, Rinaldi L, Gallo P. The safety profile of cyclophosphamide in multiple sclerosis therapy. *Expert Opin Drug Saf* 2007; 6: 183-190.
93. Low JE, Borch RF, Sladek NE. Conversion of 4-hydroperoxycyclophosphamide and 4- hydroxycyclophosphamide to phosphoramidate mustard and acrolein mediated by bifunctional catalysis. *Cancer Res* 1982; 42: 830-837.
94. Cox PJ. Cyclophosphamide cystitis-identification of acrolein as the causative agent. *Biochem Pharmacol* 1979; 28: 2045-2049.

95. Masuda H, Chancellor MB, Kihara K, Yoshimura N. 15-deoxy-Delta12,14- prostaglandin J2 attenuates development of cyclophosphamide-induced cystitis in rats. *Urology* 2006; 67: 435-439.
96. Ribeiro RA, Freitas HC, Campos MC, et al. Tumor necrosis factor and interleukin-1 mediate the production of nitric oxide involved in the pathogenesis of ifosphamide induced hemorrhagic cystitis in mice. *J Urol* 2002; 167: 2229-2234.
97. Adams JD Jr, Klaidman LK. Acrolein-induced oxygen radical formation. *Free Radic Biol Med* 1993; 15: 187-193.
98. Misonou Y, Asahi M, Yokoe S, Miyoshi E, Taniguchi N. Acrolein produces nitric oxide through the elevation of intracellular calcium levels to induce apoptosis in human umbilical vein endothelial cells: implications for smoke angiopathy. *Nitric Oxide* 2006; 14: 180-187.
99. Korkmaz A, Oter S, Sadir S, et al. Peroxynitrite may be involved in bladder damage caused by cyclophosphamide in rats. *J Urol* 2005; 173: 1793-1796.
100. Souza- Fiho MV, Lima MV, Pompeu MM, Ballejo G, Cunha FQ, Riberio RA. Involvement of nitric oxide in the pathogenesis of cyclophosphamide induced hemorrhagic cystitis. *Am J Pathol* 1997; 150: 247-256.
101. Alfieri AB, Cubeddu LX. Nitric oxide and NK(1) tachykinin receptors in cyclophosphamide-induced cystitis in rats. *J Pharmacol Exp Ther* 2000; 295: 824-829.
102. Yuan M, Smith PB, Brundrett RB, Colvin M, Fenselau C. Glutathione conjugation with phosphoramidate mustard and cyclophosphamide. A mechanistic study using tandem mass spectrometry. *Drug Metab Dispos* 1991; 19: 625-629.
103. Yousefipour Z, Ranganna K, Newaz MA, Milton SG. Mechanism of acrolein-induced vascular toxicity. *J Physiol Pharmacol* 2005; 56: 337-353.
104. Srivastava A, Shivanandappa T. Hepatoprotective effect of the root extract of *Decalepis hamiltonii* against carbon tetrachloride-induced oxidative stress in rats. *Food Chem* 2010; 118: 411-417.
105. Senthilkumar S, Devaki T, Manohar MB, Babu MS. Effect of squalene on cyclophosphamide-induced toxicity. *Clin Chim Acta* 2006; 364: 335-342.
106. Zarei M, Shivanandappa T. Amelioration of cyclophosphamide-induced hepatotoxicity by the root extract of *Decalapis hamiltonii* in mice. *Food and Chem Toxicol* 2013; 57: 179- 184.
107. Tripathi DN, Jena GB. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early

- hepatocarcinogenesis in rat: Role of Nrf2, p53, p38 and phase-II enzymes. *Mutat Res* 2010; 69-80.
108. Bhatia K, Kaur M, Atif F, Ali M, Rehman H, Rahman S, Raisuddin S. Aqueous extract of *Trigonella foenum-graecum* L. ameliorates additive urotoxicity of buthionine sulfoximine and cyclophosphamide in mice. 2006; *Food Chem Toxicol* 44: 1744-1750.
 109. Kouidhi S, Rouissi K, Hamrita B, Ouerhani S, Cherif M, Elgaaied AB. Therapeutic effects of aloe Vera plant extract against cyclophosphamide and buthionine sulfoximine induced toxicities in the bladder. *Biochem Pharmacol* 2012; 1: 1-7.
 110. Aguilar-Mahecha A, Hales BF, Robaire B. Chronic cyclophosphamide treatment alters the expression of stress response genes in rat male germ cells. *Biol Reprod* 2002; 66: 1024- 1032.
 111. Ghosh D, Das UB, Ghosh S, et al. Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: a correlative study with testicular oxidative stress. *Drug Chem Toxicol* 2002; 25: 281-292.
 112. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. *Blood* 2003; 101: 2043-2048.
 113. Shaunak S, Munro JM, Weinbren K, Walport MJ, Cox TM. Cyclophosphamide-induced liver necrosis: a possible interaction with azathioprine. *Q J Med* 1988; 67: 309-317.
 114. Malhi H, Annamaneni P, Slehria S, et al. Cyclophosphamide disrupts hepatic sinusoidal endothelium and improves transplanted cell engraftment in rat liver. *Hepatology* 2002; 112- 115.
 115. Lushnikova EL, Molodykh OP, Nepomnyashchikh LM, Bakulina AA, Sorokina YA. Ultrastructural picture of cyclophosphamide-induced damage to the liver. *Bull Exp Biol Med* 2011; 151: 751-756.
 116. Lameire N, Kruse V, Rottey S, et al. Nephrotoxicity of anticancer drugs – an underestimated problem? *Acta Clin Belg* 2011; 66: 337–345.
 117. Newton HB. Neurological complications of chemotherapy to the central nervous system. *Handb Clin Neurol* 2012; 105: 903–916.
 118. Pessayre D, Fromenty B, Berson A, et al. Central role of mitochondria in drug-induced liver injury. *Drug Metab Rev* 2012; 44: 34–87.
 119. Norman AW, Nemere I, Zhou LX, Bishop JE, Lowe KE, Maiyar AC, et al. 1,25(OH)₂- vitamin D₃, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. *J Steroid Biochem Mol Biol* 1992; 41: 231-240.

120. Garcion E, Sindji L, Leblondel G, Brachet P, Darcy F. 1,25-dihydroxyvitamin D3 regulates the synthesis of gamma-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. *J Neurochem* 1999; 73: 859-866.
121. Sardar S, Chakraborty A, Chatterjee M. Comparative effectiveness of vitamin D3 and dietary vitamin E on peroxidation of lipids and enzymes of the hepatic antioxidant system in Sprague-Dawley rats. *Int J Vitam Nutr Res* 1996; 66: 39-45.
122. Wiseman H. Vitamin D is a membrane antioxidant. Ability to inhibit iron-dependent lipid peroxidation in liposomes compared to cholesterol, ergosterol and tamoxifen and relevance to anticancer action. *FEBS Lett* 1993; 326: 285-288.
123. Lin AM, Chen KB, Chao PL. Antioxidative effect of vitamin D3 on zinc-induced oxidative stress in CNS. *Ann N Y Acad Sci* 2005; 1053: 319-329.
124. Leon J, Acuna-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. *J Pineal Res* 2005; 38: 1-9.
125. Çetinkalp Ş, Delen Y, Karadeniz M, et al. The effect of 1 α ,25(OH)₂D3 vitamin over oxidative stress and biochemical parameters in rats where Type 1 diabetes is formed by streptozotocin. *Journal of Diabetes and Its Complications* 2009; 23: 401-408.
126. Kono K, Fujii H, Nakai K, et al. Antioxidative effect of vitamin D analog on incipient vascular lesion in non-obese type 2 diabetic rats. *Am j Nephrol* 2013; 37: 167-174.
127. Mauricio D, Mandrup-Poulsen T, Nerup J. Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: A therapeutic perspective. *Diabetes/Metabolism Reviews* 1996; 12: 57-68.
128. Noyan T, Baharoğlu R, Kömüroğlu U. The oxidant and antioxidant effects of 25-hydroxyvitamin D3 in liver, kidney and heart tissues of diabetic rats. *Clin Exp Med* 2005; 5: 31-36.
129. Halicka HD, Zhao H, Li J, et al. Attenuation of constitutive DNA damage signaling by 1,25-dihydroxyvitamin D3. *Aging* 2012; 4: 270-278.
130. Krishnan AV, Trump DL, Johnson CS, Feldman D. The role of vitamin D in cancer prevention and treatment. *Endocrinol Metab Clin N Am* 2010; 39: 401-418.
131. Giardina C, Madigan JP, Godman Tierney CA, Brenner BM, Rosenberg DW. Vitamin D resistance and colon cancer prevention. *Carcinogenesis* 2012; 33: 475-482.

132. Fleet JC, Desmet M, Johnson R, Li Y. Vitamin D and cancer: a review of molecular mechanisms. *Biochem J* 2012; 221: 61-76.
133. Bao BY, Ting HJ, Hsu JW, Lee YF. Protective role of 1 alpha, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. *Int J Cancer* 2008; 122: 2699-2706.
134. Salum E, Kals J, Kampus P, et al. Vitamin D reduces deposition of advanced glycation end-products in the aortic wall and systemic oxidative stress in diabetic rats. *Diabetes Res Clin Pract* 2013; 100: 243-249.